Publications by authors named "W D Irvin"
Introduction: Tumor genomic testing (TGT) is standard-of-care for most patients with advanced/metastatic cancer. Despite established guidelines, patient education prior to TGT is frequently omitted. The purpose of this study was to evaluate the impact of a concise 4 min video for patient education prior to TGT.
View Article and Find Full Text PDFPurpose: Neither the United States nor the European oncology guidelines include details for appropriate management of hyperglycemia in cancer patients. The aim was to identify fasting and random blood glucose thresholds, and hemoglobin A1c (HbA1c) targets used by oncologists in clinical practice when managing hyperglycemia in patients with cancer undergoing chemotherapy.
Methods: This national, cross sectional study utilized a questionnaire to collect oncologists' perceptions about optimal blood glucose thresholds and HbA1c targets in patients with cancer undergoing chemotherapy.
Article Synopsis
- FOLFIRI, a treatment for metastatic colorectal cancer, was tested using a pharmacogenomic strategy to tailor irinotecan doses based on UGT1A1 genotypes to see if it could improve progression-free survival (PFS).
- In a study with 100 participants, results showed a median PFS of 12.5 months, which was shorter than expected, with variations in PFS based on genotype.
- Although a tailored irinotecan strategy showed modest improvements in PFS for certain genotypes, it did not significantly change overall treatment outcomes and shouldn't replace current standard practices for first-line treatment.
Introduction: Standard investigator-based adverse events (AE) assessment is via CTCAE for clinical trials. However, including the patient perspective through PRO (patient-reported outcomes) enhances clinicians' understanding of patient toxicity and fosters early detection of AEs. We assessed longitudinal integration of PRO-CTCAE within clinical workflow in a phase II trial.
View Article and Find Full Text PDFImportance: Observational studies of survivors of breast cancer and prospective trials of aspirin for cardiovascular disease suggest improved breast cancer survival among aspirin users, but prospective studies of aspirin to prevent breast cancer recurrence are lacking.
Objective: To determine whether aspirin decreases the risk of invasive cancer events among survivors of breast cancer.
Design, Setting, And Participants: A011502, a phase 3, randomized, placebo-controlled, double-blind trial conducted in the United States and Canada with 3020 participants who had high-risk nonmetastatic breast cancer, enrolled participants from 534 sites from January 6, 2017, through December 4, 2020, with follow-up to March 4, 2023.